Matches in Wikidata for { <http://www.wikidata.org/entity/Q58593511> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q58593511 description "artículu científicu espublizáu n'ochobre de 2018" @default.
- Q58593511 description "im Oktober 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q58593511 description "scientific article published on 18 October 2018" @default.
- Q58593511 description "wetenschappelijk artikel" @default.
- Q58593511 description "наукова стаття, опублікована в жовтні 2018" @default.
- Q58593511 name "Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response" @default.
- Q58593511 name "Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response" @default.
- Q58593511 type Item @default.
- Q58593511 label "Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response" @default.
- Q58593511 label "Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response" @default.
- Q58593511 prefLabel "Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response" @default.
- Q58593511 prefLabel "Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response" @default.
- Q58593511 P1433 Q58593511-072791CC-4792-4233-8C49-8CC488B14324 @default.
- Q58593511 P1476 Q58593511-7994B0AA-0E43-4F24-972E-0283E505294C @default.
- Q58593511 P2093 Q58593511-27A44B87-37D9-4114-B674-1463C5A04FDF @default.
- Q58593511 P2093 Q58593511-4EAF0C8C-DFE0-48B0-A228-A24BCED960D3 @default.
- Q58593511 P2093 Q58593511-7C82BB14-23BD-441D-87A1-C35753EA9325 @default.
- Q58593511 P2093 Q58593511-87C6CA99-6F3F-49F8-8EE8-F682AD17BA80 @default.
- Q58593511 P304 Q58593511-6C2B61F0-4574-4713-9BB7-4C24F77967CC @default.
- Q58593511 P31 Q58593511-0573861E-252C-46F2-95F8-52E0C7C8804D @default.
- Q58593511 P356 Q58593511-6397F3BC-DA36-4CBA-A890-CE2DD63D08F4 @default.
- Q58593511 P407 Q58593511-B0D2621A-0A18-415C-8559-3625A1BFAFFF @default.
- Q58593511 P433 Q58593511-64ABE699-8F8B-49FB-BBFF-07C748DCD6F5 @default.
- Q58593511 P478 Q58593511-6C7CCB03-EDEB-4641-87A5-4F19D3B5D65D @default.
- Q58593511 P50 Q58593511-32B8FDE3-C16F-40D2-907F-8A8A4984EC11 @default.
- Q58593511 P577 Q58593511-CBA76B24-88D8-43FC-9928-7AA32640C93B @default.
- Q58593511 P698 Q58593511-786483E8-A3BE-49AC-AE6D-FBFD67D5EADD @default.
- Q58593511 P356 BJH.15611 @default.
- Q58593511 P698 30338507 @default.
- Q58593511 P1433 Q4970200 @default.
- Q58593511 P1476 "Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response" @default.
- Q58593511 P2093 "Gabriela Carvalho" @default.
- Q58593511 P2093 "Ilana Zalcberg" @default.
- Q58593511 P2093 "Jane Dobbin" @default.
- Q58593511 P2093 "Rony Schaffel" @default.
- Q58593511 P304 "770-772" @default.
- Q58593511 P31 Q13442814 @default.
- Q58593511 P356 "10.1111/BJH.15611" @default.
- Q58593511 P407 Q1860 @default.
- Q58593511 P433 "4" @default.
- Q58593511 P478 "185" @default.
- Q58593511 P50 Q92406064 @default.
- Q58593511 P577 "2018-10-18T00:00:00Z" @default.
- Q58593511 P698 "30338507" @default.